Literature DB >> 1819999

Delayed insulin absorption due to subcutaneous edema.

C R Ariza-Andraca1, E Altamirano-Bustamante, A C Frati-Munari, P Altamirano-Bustamante, A Graef-Sánchez.   

Abstract

A prospective study to determine if subcutaneous edema interferes with insulin absorption was performed. Forty-six patients entered the study. Three groups were formed. Twenty patients with generalized edema (Group 1), ten of them with non-insulin dependent diabetes mellitus (NIDDM). Twenty patients without edema (Group II). 10 of them with NIDDM; and six patients with mild edema (Group III). The disappearance of I125-insulin was measured throughout 360 minutes. The rate of absorption in group I was significantly lower and delayed than in group II. The amount of insulin absorbed at 360 minutes was 3 to 4 fold lower in group I than in group II (p 0.001). Group III had intermediate values. The peak of plasma I125-insulin level was 3 to 4 fold lower in group I than group II. The impairment of insulin absorption in subjects with edema was more evident in those with NIDDM. In conclusion, this study demonstrates that subcutaneous edema impairs insulin absorption. Insulin absorption from subcutaneous tissue varies due to several conditions, resulting in a difficult glycemic control. Previous studies have shown that insulin absorption is affected by several factors as the site of injection, room and skin temperature, physical exercise, the thickness of adipose tissue, local massage, and local degradation of insulin. Edema due to chronic complications such as nephropathy and cardiopathy often occurs in long-standing diabetic subjects. However, the effects of edema of the skin and subcutaneous tissue on insulin absorption has not been previously examined. The aim of this study was to assess if edema affects the absorption of insulin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1819999

Source DB:  PubMed          Journal:  Arch Invest Med (Mex)        ISSN: 0066-6769


  13 in total

Review 1.  Stress hyperglycaemia.

Authors:  Kathleen M Dungan; Susan S Braithwaite; Jean-Charles Preiser
Journal:  Lancet       Date:  2009-05-23       Impact factor: 79.321

2.  Hyperglycemia control of the nil per os patient in the intensive care unit: introduction of a simple subcutaneous insulin algorithm.

Authors:  Sarah Kim; Robert J Rushakoff; Mary Sullivan; Heidemarie Windham
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

Review 3.  Glycemic variability and glycemic control in the acutely ill cardiac patient.

Authors:  Jared Moore; Kathleen Dungan
Journal:  Heart Fail Clin       Date:  2012-08-09       Impact factor: 3.179

4.  A comparison of continuous intravenous insulin and subcutaneous insulin among patients with type 2 diabetes and congestive heart failure exacerbation.

Authors:  Kathleen M Dungan; Kwame Osei; Trudy Gaillard; Jared Moore; Philip Binkley
Journal:  Diabetes Metab Res Rev       Date:  2015-01       Impact factor: 4.876

5.  An Injectable Microparticle Formulation Provides Long-Term Inhibition of Hypothalamic ERK1/2 Activity and Sympathetic Excitation in Rats with Heart Failure.

Authors:  Youssef W Naguib; Yang Yu; Shun-Guang Wei; Angie Morris; Brittany E Givens; Aml I Mekkawy; Robert M Weiss; Robert B Felder; Aliasger K Salem
Journal:  Mol Pharm       Date:  2020-08-04       Impact factor: 4.939

6.  International recommendations for glucose control in adult non diabetic critically ill patients.

Authors:  Carole Ichai; Jean-Charles Preiser
Journal:  Crit Care       Date:  2010-09-14       Impact factor: 9.097

7.  Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.

Authors:  Mirjam K Rommers; Netty Van der Lely; Toine C G Egberts; Patricia M L A van den Bemt
Journal:  Crit Care       Date:  2006-06-21       Impact factor: 9.097

Review 8.  Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability.

Authors:  A K J Gradel; T Porsgaard; J Lykkesfeldt; T Seested; S Gram-Nielsen; N R Kristensen; H H F Refsgaard
Journal:  J Diabetes Res       Date:  2018-07-04       Impact factor: 4.011

9.  An injectable microparticle formulation for the sustained release of the specific MEK inhibitor PD98059: in vitro evaluation and pharmacokinetics.

Authors:  Youssef W Naguib; Brittany E Givens; Giang Ho; Yang Yu; Shun-Guang Wei; Robert M Weiss; Robert B Felder; Aliasger K Salem
Journal:  Drug Deliv Transl Res       Date:  2021-02       Impact factor: 4.617

Review 10.  Forum for Injection Technique and Therapy Expert Recommendations, India: The Indian Recommendations for Best Practice in Insulin Injection Technique, 2017.

Authors:  Nikhil Tandon; Sanjay Kalra; Yatan Pal Singh Balhara; Manash P Baruah; Manoj Chadha; Hemraj B Chandalia; K M Prasanna Kumar; S V Madhu; Ambrish Mithal; Rakesh Sahay; Rishi Shukla; Annamalai Sundaram; Ambika G Unnikrishnan; Banshi Saboo; Vandita Gupta; Subhankar Chowdhury; Jothydev Kesavadev; Subhash K Wangnoo
Journal:  Indian J Endocrinol Metab       Date:  2017 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.